Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02087579 · ClinicalTrials.gov registry record · Phase 1
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 305
- Enrollment target
NCT02087579: Completed Phase 1 study, sponsored by Janssen Research & Development.
NCT02087579 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 305 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (408% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02087579, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 305 participants
- Enrollment target
Study Summary
The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after dosing. In addition, comparison of capillary drug concentrations vs. venous drug concentrations will be performed for aripiprazole, olanzapine, paliperidone, quetiapine, risperidone and their relevant metabolites.
Primary Outcome
Venous blood samples will be collected at 8 scheduled time points after dosing and compared to fingerstick-based capillary blood samples collected at 6 scheduled time points after dosing.
Interventions
- DRUG Aripiprazole, oral formulation
- DRUG Olanzapine, oral formulation
- DRUG Paliperidone, oral formulation
- DRUG Paliperidone, LAI
- DRUG Quetiapine, oral formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
What the finished NCT02087579 record still lists
NCT02087579 is an interventional study that assigns participants to a tested intervention. The registered 305 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (408% higher).
The record links to 0 conditions, and to 5 interventions - of which Aripiprazole, oral formulation is the first listed.
NCT02087579 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02087579 about?
NCT02087579 is a clinical study titled "Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants". The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after dosing. In addition, comparison of capillary drug concentrations vs. venou...
What is the current status of trial NCT02087579?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 305 participants. The study started on 2014-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02087579?
The interventions under investigation include: Aripiprazole, oral formulation (DRUG), Olanzapine, oral formulation (DRUG), Paliperidone, oral formulation (DRUG), Paliperidone, LAI (DRUG), Quetiapine, oral formulation (DRUG).
Who is sponsoring clinical trial NCT02087579?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02087579's enrollment target sits among peer trials
305 124th of 2000 higher than 1,877 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04107181 · 305 participants · NA
Pilot Study for Speculum Free Cervical Cancer Screening
- NCT05399056 · 305 participants · NA
Improving Participation in Pulmonary Rehabilitation Through Peer Support and Storytelling
- NCT05078970 · 306 participants · NA
Advancing Suicide Intervention Strategies for Teens During High Risk Periods
- NCT05843695 · 306 participants · NA
Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia